Cantor Fitzgerald Has Weak Outlook for CRSP FY2025 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for CRISPR Therapeutics in a report released on Wednesday, February 19th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will post earnings per share of ($6.91) for the year, down from their prior estimate of ($5.08). Cantor Fitzgerald currently has a “Neutral” rating on the stock. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.03) per share.

A number of other research firms also recently weighed in on CRSP. Evercore ISI upgraded CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and raised their price target for the company from $60.00 to $99.00 in a research report on Friday, February 14th. Barclays raised their price objective on CRISPR Therapeutics from $55.00 to $56.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. Royal Bank of Canada reduced their price objective on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research note on Wednesday, February 12th. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Finally, Truist Financial raised their price objective on CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $74.40.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP opened at $50.46 on Friday. The stock’s 50-day simple moving average is $42.16 and its two-hundred day simple moving average is $46.07. CRISPR Therapeutics has a twelve month low of $36.52 and a twelve month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the transaction, the chief executive officer now directly owns 181,540 shares in the company, valued at $10,002,854. The trade was a 7.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB purchased a new position in CRISPR Therapeutics in the 3rd quarter worth approximately $40,000. Darwin Wealth Management LLC purchased a new position in CRISPR Therapeutics in the 3rd quarter worth approximately $43,000. Highline Wealth Partners LLC bought a new stake in CRISPR Therapeutics in the 4th quarter worth approximately $39,000. Western Pacific Wealth Management LP grew its position in CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after purchasing an additional 500 shares during the period. Finally, Eastern Bank bought a new stake in CRISPR Therapeutics in the 3rd quarter worth approximately $70,000. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.